Purchase Order 140D0425P0049
- Not listed
- The National Center for Advancing Translational Sciences (NCATS), a civilian agency within the U.S. Department of Health and Human Services, awarded a firm-fixed-price purchase order contract worth $18,028.80 to Reaction Biology Corporation, a self-certified small disadvantaged business. The contract, which does not have a set-aside designation, was awarded on June 5, 2019, with a completion date of December 13, 2019. Reaction Biology Corporation, a drug discovery contract research organization,...
- This is a $19,840.00 firm-fixed price purchase order awarded by the National Center for Advancing Translational Sciences (NCATS), part of the National Institutes of Health (NIH), to Reaction Biology Corporation, a self-certified small disadvantaged business. The contract is for biochemical kinase assays on 160 compounds to determine their inhibitory activity against the kinases LATS1, LATS2, and AKT, which will inform the development of potential anti-cancer agents. This award was a...
- The Department of Health and Human Services' National Institutes of Health National Center for Advancing Translational Sciences awarded Reaction Biology Corporation a $11,304 purchase order contract to provide unspecified services or products in Malvern, Pennsylvania. As a component of NIH, NCATS works to develop innovations that enhance the development, testing, and implementation of diagnostics and therapeutics across a wide range of diseases and conditions. Reaction Biology Corporation will...
- This $29,376 firm-fixed-price purchase order was awarded by the National Center for Advancing Translational Sciences (NCATS), a component of the National Institutes of Health (NIH), to Reaction Biology Corporation, a self-certified small disadvantaged business. The award is to obtain kinase hotspot assay compound testing services from Reaction Biology. This contract is not associated with a larger vehicle. The purpose is to test 120 novel small molecule compounds for inhibitory activity...
- Reaction Biology Corporation has been awarded a $100,560 firm fixed price purchase order by the Department of Health and Human Services' National Institutes of Health National Center for Advancing Translational Sciences to provide GAMMA 33P ATP Kinase Assay and NanoBRET Kinase Assay testing services. As a prime contractor, Reaction Biology will utilize its Kinase HotSpot and Methyltransferase HotSpot platforms to test libraries of novel compounds against panels of wild-type kinases and...
- This is a firm fixed-price purchase order awarded by the National Institutes of Health's National Center for Advancing Translational Sciences to Reaction Biology Corporation, a self-certified small disadvantaged business. The $21,027.68 contract is for the testing of 2 compounds against a selected kinase panel in a biochemical gamma 33P-ATP kinase assay. Reaction Biology specializes in enzyme activity assays and has previously provided kinase inhibition testing, cancer cell line screening, and...
- This is a $118,430.00 firm fixed-price purchase order awarded by the Department of Health and Human Services' National Institutes of Health National Center for Advancing Translational Sciences to Reaction Biology Corporation, a self-certified small disadvantaged business. The contract is for testing 15 novel small molecule compounds using Reaction Biology's proprietary Kinase HotSpot assay platform. This work supports translational research efforts across the NIH. The purchase order was...
- This $19,833.68 firm fixed-price purchase order contract was awarded by the Department of Health and Human Services' National Institutes of Health (NIH) National Center for Advancing Translational Sciences (NCATS) to Reaction Biology Corporation, a self-certified small disadvantaged business. The contract is for profiling 10 BTK (Bruton's tyrosine kinase) inhibitors against a panel of 20 kinases. Reaction Biology is a drug discovery contract research organization that specializes in enzyme...
- Reaction Biology Corporation was awarded a $16,480.80 firm fixed price purchase order by the National Institutes of Health's National Center for Advancing Translational Sciences to test 35 novel small molecule compounds for inhibition of three wild-type kinase enzymes. Under the contract, Reaction Biology will utilize its Kinase HotSpot assay platform to test each compound at 10 different doses and provide one comprehensive report detailing results against the three kinases. The testing services...
- This is a $35,817.60 firm-fixed-price purchase order awarded by the National Institutes of Health (NIH) National Center for Advancing Translational Sciences (NCATS) to Reaction Biology Corporation, a self-certified small disadvantaged business. The contract is for methyltransferase panel screening using Reaction Biology's proprietary Methyltransferase HotSpot assay platform to support NCATS' Early Translation Branch (ETB) and the DPI_SARS-CoV-2_Variant Trace project. This non-competitive award...
The National Center for Advancing Translational Sciences (NCATS), a division of the National Institutes of Health, awarded a $59.8K firm fixed-price purchase order to Reaction Biology Corporation for bioactive small molecule development services. The contract, awarded on September 19, 2025, with an ultimate completion date of September 22, 2026, encompasses Gamma 33P ATP kinase assay and NanoBRET kinase assay services to be performed at the contractor's facility in Malvern, Pennsylvania. This procurement was structured as a sole-source award under 41 U.S.C. 1901 and FAR 13.106-1(b)(1), with no small business set-aside applied. The government justified the sole-source approach based on the requirement for data consistency and methodology continuity in an ongoing development project, necessitating the same specialized assay services previously provided by Reaction Biology Corporation to maintain comparable sample analysis throughout the project duration. Reaction Biology Corporation, a contract research organization specializing in advanced biochemical and preclinical research services, has established itself as a key provider for NCATS-funded kinase and enzyme research initiatives. The company, registered as a self-certified small disadvantaged business, operates proprietary screening platforms such as Kinase HotSpot and Methyltransferase HotSpot that enable comprehensive enzymatic testing for potential therapeutic compounds. The firm's portfolio of federal contracts with NCATS and the National Institute on Drug Abuse demonstrates consistent technical capability in delivering complex scientific testing services, with prior awards ranging from $11K to $166.5K for similar kinase profiling, biochemical assays, and cellular screening projects supporting translational research across multiple therapeutic domains.
Name | Description | Solicitation Number | FederalAgency | Type | PostedDate |
|---|---|---|---|---|---|
Notice of Intent to Sole Source | 140D0425Q0732 | Department of the Interior Departmental Offices Interior Business Center | Special Notice 1/1 | 8/15/25, 3:04 PM |
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $59.8k | 9/19/25 |